

## GENERAL INFORMATION

### Registration

The registration fee covers course participation, coffee/tea, lunch. Registration can be done via the congress website, [www.essr2017.eu](http://www.essr2017.eu). Registration for the full ESSR congress (15-17 June) gives you access to this symposium as well.

### Registration fees

Early Bird to 10 April 2017: EUR 150  
Mid Bird 10 April to 13 June 2017: EUR 170  
Full Price After 13 June 2017: EUR 190

Cancellations after 12 May 2017 will be reimbursed minus EUR 25 administration costs. Cancellation is only possible by e-mail through [essr2017@congresscompany.com](mailto:essr2017@congresscompany.com)

### Venue

Beurs van Berlage  
Damrak 243  
1012 ZJ Amsterdam  
The Netherlands

### Accreditation

Accreditation is requested at UEMS.

### Contact



[www.congresscompany.com](http://www.congresscompany.com)  
[essr2017@congresscompany.com](mailto:essr2017@congresscompany.com)

Enabled by:



[www.essr2017.eu](http://www.essr2017.eu)



16 June  
2017

## SYMPOSIUM ONE DAY ON NEW STRATEGIES IN THE TREATMENT OF COLORECTAL LIVER METASTASES

Beurs van Berlage, Amsterdam, the Netherlands

[www.essr2017.eu](http://www.essr2017.eu)

## DEAR COLLEAGUES,

We are very pleased to invite you to the symposium **One day on new strategies in the treatment of colo-rectal liver metastases**, to be held in the 'Beurs van Berlage' in Amsterdam, on Friday June 16, 2017.

The "One day....." symposia have become a tradition in Amsterdam. The aim of these symposia is to provide an update on selected topics in liver surgery. This year we address the various therapies currently available for the treatment of colo-rectal liver metastases.

Surgical removal of the metastases remains the gold standard for cure. Although the criteria for resectability are straightforward, assessment of resectability may vary even among expert panels. Initially unresectable metastases are amenable to neoadjuvant systemic treatment in order to down-size tumor. From the liver side, several techniques can be used to preoperatively up-size parenchyma of the future remnant liver such as portal vein embolization and more recently, ALPPS. The laparoscopic approach has advanced and is now used also for the larger liver resections. The margin status and concomitant resection of extra-hepatic disease have been debated in the light of modern chemotherapy although the role of perioperative chemotherapy is still under discussion. Identification of RAS status of the tumor besides other molecular and clinical parameters offer the prospect of personalized care of patients with colo-rectal liver metastases. Several locoregional therapies have emerged as an adjunct to liver resection or as alternative strategies when a curative resection is not feasible. Radiofrequency ablation (RFA) has been widely used for local destruction of liver metastases and can be applied percutaneously or intra-operatively, alone or in combination with resection. Irreversible electroporation (Nanoknife) and stereotactic body radiation therapy (SBRT) are alternative methods to locally destruct tumor.

The afternoon program is devoted to Selective Internal Radiation Therapy (SIRT) using microspheres loaded with the high-energy beta-emitting radioisotope yttrium-90. SIRT is increasingly used in the management of patients with unresectable colo-rectal liver metastases. When used in the unilateral setting, it may even induce contralateral hypertrophy allowing secondary resection.

This year, the symposium is part of the 52nd International Meeting of the European Society for Surgical Research, which will be held from June 14-17 in the 'Beurs van Berlage' in Amsterdam. The Beurs van Berlage is a historical building in the center of Amsterdam and offers the perfect venue for this international meeting. We would like to thank our colleagues from world leading centers for coming to Amsterdam to share their experience with us in this symposium.

We look forward to welcoming you in Amsterdam on June 16<sup>th</sup> 2017,  
*Thomas van Gulik, Joost Huiskens, Pieter Tanis and Kees Punt*

## Faculty

*René Adam, Hôpital Universitaire Paul Brousse, Villejuif, France*  
*Marc Besselink, Academic Medical Center, Amsterdam, The Netherlands*  
*Yun Chun, MD Anderson Cancer Center, Houston, USA*  
*Benjamin Garlipp, University Hospital Magdeburg, Germany*  
*Thomas Gruenberger, Rudolf Foundation Hospital, Vienna, Austria*  
*Thomas van Gulik, Academic Medical Center, Amsterdam, the Netherlands*  
*Derek Manas, Newcastle Hospitals, Newcastle, UK*  
*Martijn Meijerink, VU medical center, Amsterdam, the Netherlands*  
*Bernard Nordlinger, Hospital Ambroise Pare, Paris, France*  
*Fernando Pardo, University of Navarra, Pamplona, Spain*  
*Kees Punt, Academic Medical Center, Amsterdam, the Netherlands*  
*Myrddin Rees, Hamsphire Hospitals, Basingstoke, UK*  
*Theo Ruers, Netherlands Cancer Institute, Antonie van Leeuwenhoek, Amsterdam, the Netherlands*  
*Michael Schön, Hospital of Karlsruhe, Germany*  
*Pieter Tanis, Academic Medical Center, Amsterdam, the Netherlands*  
*Henrike Westerveld, Academic Medical Center, Amsterdam, the Netherlands*

## SYMPOSIUM ONE DAY ON NEW STRATEGIES IN THE TREATMENT OF COLORECTAL LIVER METASTASES

**Beurs van Berlage, Amsterdam, June 16, 2017**

### Program

#### 08.00 - 09.00 Registration, coffee and tea

09.00 - 09.05 Welcome *T. van Gulik*

#### 09.05 - 10.45 Chair: B. Nordlinger, T. van Gulik

09.05 - 09.30 Liver resection for CRLM - The gold standard *M. Rees*

09.30 - 09.55 Unresectable CRLM - How is it defined *T. Gruenberger*

09.55 - 10.20 Strategies to increase resectability of CRLM (ALPPS, PVE, RFA) *T. van Gulik*

10.20 - 10.45 Laparoscopic liver resection for CRLM - Where are the limits? *M. Besselink*

#### 10.45 - 11.15 Coffee break

#### 11.15 - 12.55 Chair: T. Ruers, M. Besselink

11.15 - 11.40 The margin issue in resected CRLM *P. Tanis*

11.40 - 12.05 Concomitant resection of extra-hepatic disease *R. Adam*

12.05 - 12.30 Systemic therapy - Strategies to convert unresectable into resectable disease *C. Punt*

12.30 - 12.55 Peri-operative chemotherapy - what to do now *B. Nordlinger*

#### 12.55 - 13.45 Lunch

#### 13.45 - 15.25 Chair: D. Manas, P. Tanis

13.45 - 14.10 Ras mutations - the key to tailored approach *Y. Chun*

14.10 - 14.35 Heat ablative therapies - Where are we standing *T. Ruers*

14.35 - 15.00 Nanoknife treatment of CRLM - The new kid on the block *M. Meijerink*

15.00 - 15.25 Stereotactic body radiation therapy - When does it come in *G. Westerveld*

#### 15.25 - 15.55 Tea break

#### 15.55 - 17.25 Chair: T. Gruenberger, M. Meijerink

15.55 - 16.20 SIRT Technical considerations *F. Pardo*

16.20 - 16.45 SIRT for CRLM *D. Manas*

16.45 - 17.10 SIRT and ALPPS *M. Schoen*

17.10 - 17.25 SIRT for induction of parenchymal liver hypertrophy *B. Garlipp*

17.25 - 17.30 Closure

#### 17.30 - 18.30 Cocktails